Recordati Industria Chimica e Farmaceutica

Report Publication Announcement • Mar 25, 2021

RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

Milan, 25 th March 2021 – Please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 18th March 2021:

• (i) the 2020 Corporate Governance Report and Ownership Structure pursuant to article 123-bis of Italian Legislative Decree no. 58 of 24th February 1998;
• (ii) the Report on the Remuneration Policy and the remuneration paid pursuant to article 123-ter, paragraphs 3-bis and 6, of Italian Legislative Decree no. 58 of 24th February 1998;
• (iii) the Directors' Report relating to item no. 2 (Report on the Remuneration Policy and the remuneration paid) of the agenda of the Ordinary Shareholders' Meeting called for 20th April 2021, which again includes, as its annex, the Report on the Remuneration Policy and the remuneration paid referred to in point (ii),

are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it, the first report in the Corporate Governance – Report on Corporate Governance and the Ownership Structure section; the second report in the Corporate Governance – Remuneration section; and the third report in the Investors - Shareholders' Meeting section) and on the '' storage mechanism ().

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media Relations Federica De Medici Studio Noris Morano (39) 02 48787146 (39) 02 76004736, (39) 02 76004745

e-mail: investorelations@recordati.it e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Ph. (39) 02 487871 Fax (39) 02 40073747 www.recordati.com

Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l